Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT sub-analysis: Prevention of atherosclerosis by SGLT2 inhibitor
jRCT1071220089Recruiting
- Sponsor
- Koichi Node
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in type 2 diabetes mellitus (T2DM) and atherosclerosis comparing Suglat (ipragliflozin) arm with Control arm (non-SGLT2 standard of care) (2 arms). Primary endpoint: Carotid artery intima-media thickness (IMT) at 24 months. Started Jan 2023; status: recruiting.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)atherosclerosis
Beyond the preview
Go deeper on jRCT1071220089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071220089.